Evidence map›Paper›PMID 38769831›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2024

[Advances of Molecular Targeted Therapy in EGFR-mutated Squamous Cell Lung Cancer].

Bingwan Xiong, Wenfei Ke, Wenyang Jiang

Abstract readReviewEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bingwan XiongDepartment of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Wenfei KeDepartment of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Wenyang JiangDepartment of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) is a prevalent tumour type in our country, with lung squamous carcinoma being a commonly observed NSCLC subtype besides lung adenocarcinoma. Epidermal growth factor receptor (EGFR) is a significant driver gene in lung cancer, and EGFR mutation frequency is considerably lower in lung squamous carcinoma in comparison to lung adenocarcinoma. Although targeted therapy against EGFR has demonstrated significant advancements in lung adenocarcinoma, while progress in lung squamous carcinoma has been relatively sluggish. This paper reviews recent studies on molecular targeted therapy for EGFR-mutated lung squamous carcinoma and summarises the efficacy of EGFR-tyrosine kinase inhibitors (TKIs) in treating squamous carcinoma of the lung, in order to provide a reference for treating patients with EGFR-mutated squamous carcinoma of the lung.
.

Indexed as

Carcinoma, Squamous CellErbB ReceptorsLung NeoplasmsMolecular Targeted TherapyMutationProtein Kinase InhibitorsCarcinoma, Non-Small-Cell LungHumansEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsEpidermal growth factor receptorEpidermal growth factor receptor-tyrosine kinase inhibitorsLung neoplasmsTargeted therapy

Identifiers

PMID38769831
PMCPMC11110274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.